主页 > 医学文档 >
Oxford BioMedica神经修复新药在动物试验中取得良好
研究者在加州的一次科学会议上公布的老鼠试验数据显示，该公司的产品Innurex能使神经高度再生。
该产品可以刺激神经细胞产生新的联系，有可能被列为第一线的治疗药物，为好莱坞影星克里斯多夫李维（Christopher Reeve）这样的脊椎受损患者带来了福音。
不过在该公司将该产品商业化之前，还要有很多工作尚待进行。许多在动物身上取得良好效果的试验性药物都对人体无效，其他机构曾进行的神经损伤修复试验最后都以失败告终。
Oxford BioMedica不久后将会把试验结果刊登在行业刊物上。
Oxford BioMedica Presents Proof-of-Principle Data for its Innurex Nerve Repair Programme at the 10th International Symposium on Neural Regeneration
Oxford BioMedica announced today that interim preclinical data from the Innurex nerve repair programme are being presented by Prof. Malcolm Maden of King's College London at the 10th International Symposium on Neural Regeneration which is being held at the Asilomar Conference Center, Pacific Grove, California. The data, which will shortly be sent for peer-reviewed publication, show that Innurex is able to induce nerve regrowth at the site of injury in a model of nerve damage. These results strongly support the technical principle of Innurex which is designed for nerve repair and the treatment of spinal injury.
Within the field of neurobiology nerve repair has been a long sought goal for the treatment of nerve damage and spinal injury. The aim is to induce nerve cells to regrow and bridge sites of injury thereby reconnecting the nerve fibres and restoring function. Results obtained to date by other groups based on different mechanisms of nerve repair have shown only inefficient induction of regrowth of nerves and very limited restoration of function.
Innurex is a product comprising Oxford BioMedica's LentiVector delivery system carrying the RAR gene. The Company acquired exclusive rights to the RAR gene from King's College London where the initial observation that this gene could programme nerve cells to regrow in vitro was made. The new data are the first in vivo data to come from the Innurex programme and they indicate that Innurex has the potential to be a first-in-class product for nerve repair.
Commenting on the results Prof. Maden said "The combination of the RAR gene and the very efficient LentiVector delivery system has produced a high level of axon (nerve) regrowth. There is every chance that this is enough for restoration of function to damaged nerves and the Company should have functional data shortly".
Prof. Alan Kingsman, Oxford BioMedica's Chief Executive said "The Innurex programme has gone from initial observation to proof of principle in a good animal model in less than two years. This is a remarkable achievement by the King's team and the Oxford BioMedica staff. Innurex is on course for clinical development within the next 12 months". [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-30 17:33
医学,生命科学网